Easton Pharmaceuticals, Inc. (EAPH)

White-LogoA specialty pharmaceutical company, Easton Pharmaceuticals, Inc designs, develops, and markets topical health care products. These premium products provide various therapeutic benefits using the company’s proprietary gel formulation to deliver transdermal effects. In 2013, the Toronto, Canada-based company announced that it has also made initiatives to enter the medical marijuana sector.

The current products of Easton Pharmaceuticals cater to a variety of health issues. It has an anti-wrinkle cream called Skin Renou HA, an arthritis- and body pain-reliever called Kenestrin Gel, a motion sickness gel called Nauseasol, and a female sexual enhancement gel called Viorra. All of these are applied through the unique transdermal delivery system.

Aside from these, two products in the company’s pipeline are XILIVE, an early-stage cancer drug, and Femlife, a transdermal drug to treat Female Sexual Arousal Disorder (FSAD).

In June 2013, Easton Pharmaceuticals announced its intent to open medical cannabis clinics in the US and Canada. More recently, in June 2014, the company has started discussing investment proposals, including one to a medical marijuana dispensary in Michigan.

The company has also made an investment in AMFIL Technologies, the manufacturer of the mPact-GROzone Antimicrobial System. This system utilizes ozone technologies to minimize pathogens and pests in marijuana growing facilities.

Founded in 1997 as LAM Pharmaceutical Corp, Easton Pharmaceuticals changed to its current name in 2010. It is currently being traded in the OTC markets under the symbol EAPH, with a market cap of USD 1.26 M.

Among the company’s key executives are Carla Pepe, CEO and President; John Adams, CFO; Kent A. Deuters, COO; Dr. Peter J. Rothbart, Treasurer; Dr. Daniel Bagi, Senior Executive Physician Consultant; and Dr. Lilla Albert, Chief Marketing and Technology Officer.


Yahoo! Finance: EAPH News

Latest Financial News for EAPH

Easton Provides Update on the Closing of its Agreement To Acquire Commercial Bakery

TORONTO, ON / ACCESSWIRE / April 12, 2019 / Easton Pharmaceuticals, Inc. (OTC PINK: EAPH) provides update on the closing of its agreement to acquire a commercial bakery with existing revenues and projected to reach over $20,000,000 within 12 months. Easton announced earlier this week that its legal counsel believed that all documents would be completed this week with signatures and exchange of documents. Easton is acquiring a revenue generating commercial bakery and food preparation company in Toronto, Ontario, Canada.

Easton Provides Update on the Closing of its Agreement To Acquire Commercial Bakery with Projected Revenues Over $20,000,000 per Year and Positioned to Enter the Cannabis Edibles Market

TORONTO, ON / ACCESSWIRE / April 8, 2019 / Easton Pharmaceuticals Inc. (OTC PINK: EAPH) provides update on the closing of its agreement to acquire a commercial bakery with existing revenues and projected to reach over $20,000,000 within 12 months. Easton announced earlier in March that it had signed a Definitive Agreement to acquire a commercial bakery and food preparation company with existing revenues and projected revenues in excess of $20,000,000 over the next 12 months. Easton's legal counsel believes that all documents will be completed this week with signatures and exchange of documents.

Easton Announces Signing of Joint Venture Agreement for the Purchase and Development of 9 Townhomes with Revenue in Excess of $4 Million and Provides Update on its Framing Contract with Revenues of $770K for Q1

TORONTO, ON / ACCESSWIRE / April 2, 2019 / Easton Pharmaceuticals Inc. (OTC PINK: EAPH) Announces that is has signed a Joint Venture Agreement for the purchase and development of 9 townhomes in Welland, Ontario and provides update on its ongoing contract for the framing of 150 homes in Whitby, Ontario. Easton is pleased to have signed a joint venture agreement for the purchase and development of 9 townhomes in Welland, Ontario, which is less than 30 minutes from Niagara Falls, Canada. This will be the second development project the Company has commenced, after its acquisition of approximately 3 acres in Cobourg, Ontario, where Easton is converting an existing heritage mansion into 6 luxurious residential condominium units, that will generate $2 million in profit for the Company and is expected to generate over $30 million over 3 years with the development of approximately 42 residential units.

Easton Signs LOI with Licensed Producer of Cannabis to Expand its Operations and Participate in its Cannabis Edibles Division

TORONTO, ON / ACCESSWIRE / March 27, 2019 / Easton Pharmaceuticals Inc. (OTC PINK: EAPH) announces that it has signed a Letter of Intent with a Licensed Producer of Medical Marijuana in Canada, whereby Easton will participate in the LP's expansion plans. In its ongoing efforts to diversify and enter into other lucrative sectors, Easton is pleased to announce that it has signed a Letter of Intent with a Canadian Licensed Producer of Cannabis, already in revenues from its cultivation and sales activities. Easton has been in discussions with this LP since January and has finally concluded an LOI whereby Easton, through its Development Division, will undertake the build-out of the LP's new Oil Extraction facility in exchange for an ownership interest in the LP.

Easton Announces Filing of Its Financial Statements for the Year Ended December 31, 2018 with a Revenue Increase of 145% Over 2017 and Provides General Business Update

Easton realized revenues of $378,589 USD during 2018, an increase in revenues over 145% from 2017. The Company's revenues primarily derived during the last 2 quarters from activities generated from its Georgina property, as well as from its construction contract to frame 150 new homes, through its Real Estate and Development Division. Easton's management announced last year that it would be entering into additional lucrative market segments that its directors have experience in.